• Explore /
  • Poster
  • / First-in-human clinical trial design of a first-in-class theranostic approach with a peptide-based radioligand targeting CA IX-expressing tumors.

First-in-human clinical trial design of a first-in-class theranostic approach with a peptide-based radioligand targeting CA IX-expressing tumors.

Abstract Poster

Authors

null

Darren R. Feldman

Memorial Sloan Kettering Cancer Center, New York, NY

Darren R. Feldman , Ben Tran , Louise Emmett , Michael S Hofman , Pierre Olivier , Hakim Mahammedi , Ivana Galetic , Anna Pokorska-Bocci , Florilene Bouisset , Kathrin Gollmer , Mariya Pavlyuk , Libuse Tauchmanova , Ken Herrmann

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Radiopharmaceuticals

Clinical Trial Registration Number

NCT05706129

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS3160)

DOI

10.1200/JCO.2023.41.16_suppl.TPS3160

Abstract #

TPS3160

Poster Bd #

354b

Abstract Disclosures

Similar Posters

First Author: Brian M. Shuch

First Author: Darren R. Feldman

First Author: Tian Zhang

Poster

2014 Genitourinary Cancers Symposium

Results of a feasibility study of I-124 girentuximab in metastatic clear cell renal cell carcinoma (m ccRCC).

Results of a feasibility study of I-124 girentuximab in metastatic clear cell renal cell carcinoma (m ccRCC).

First Author: Stephen Michael Keefe